Skip to main content
OpenTrials
Completed

NCT Number: NCT04720001

Florbetaben PET Imaging in PPA

The purpose of this research is to better understand how dementia affects activity in different parts of the brain.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Primary Progressive Aphasia Alzheimer Disease Aphasia Aphasia, Primary Progressive Brain Diseases Central Nervous System Diseases Communication Disorders Dementia Language Disorders Mental Disorders Nervous System Diseases Neurobehavioral Manifestations Neurocognitive Disorders Neurodegenerative Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms Speech Disorders Tauopathies

Age range

18 year–100 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Chicago - American School Building

Chicago, Illinois, 60637, United States

About this study

This study will examine Positron Emission Tomography (PET) imaging with Florbetaben F18. Florbetaben F18 is a radioactive tracer that binds to particles in your brain. This process displays activity in the brain. Florbetaben F18 is a PET amyloid imaging agent approved by the United States Food and Drug Administration (FDA) to estimate the amount of beta-amyloid plaque in adult patients who are being evaluated for Alzheimer's disease and other causes of cognitive decline. The purpose of this research is to better understand how dementia affects activity in different parts of the brain. Currently, the scientific community is limited by how well it can see inside the brain. The use of a PET scan better helps us understand what the brain looks like in a diseased state. Participation in the study will help to understand what brain activity looks like, especially around language regions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants must have a diagnosis of PPA or a related dementia syndrome

Exclusion criteria

  • Pregnant
  • Breastfeeding
  • Receiving radiation clinically

Treatment and study plan

Florbetaben F18

Drug

A single injection of 8.1mCi of florbetaben F18 will be administered by intravenous bolus injection

Other names: trade name NeuraCeq

PET

Device

PET Scan for brain imaging

Primary outcomes

  1. Amyloid plaque levels in PPA participants

    Time frame: 2 Years

    Amyloid plaque aggregation as measured by florbetaben F18 standard uptake value ratio cerebral and cerebellar regions of interest.

Sponsors and collaborators

Lead sponsor

University of Chicago

Other

Collaborators

  • Northwestern University

Registry information

Official study title

Florbetaben PET Imaging in Primary Progressive Aphasia

Important dates

Study start
2018
Primary completion
2021
Study completion
2021
First posted
Jan 22, 2021
Registry last updated
Oct 16, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.